Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Senseonics Holdings (NYSE American: SENS) announced a virtual KOL event on October 25, 2024, at 11:00am ET to discuss the Eversense® 365 Continuous Glucose Monitoring (CGM) system. This next-generation system, recently cleared by the FDA for people with Type 1 and Type 2 diabetes aged 18 and older, is the world's first one-year CGM system.
The event will feature Dr. David T. Ahn from Hoag Medical Group and Dr. Jeff Ciaramita from Mercy health system, along with company management. They will highlight Eversense 365 in clinical practice and provide an overview of Senseonics' commercial collaboration with Mercy. A live Q&A session will follow the presentations.
Senseonics Holdings (NYSE American: SENS) ha annunciato un evento virtuale KOL il 25 ottobre 2024, alle 11:00 ET, per discutere del sistema di monitoraggio continuo della glicemia Eversense® 365 (CGM). Questo sistema di nuova generazione, recentemente autorizzato dalla FDA per persone con diabete di tipo 1 e tipo 2 di età pari o superiore a 18 anni, è il primo sistema CGM al mondo con durata di un anno.
L'evento vedrà la partecipazione del Dr. David T. Ahn del Hoag Medical Group e del Dr. Jeff Ciaramita del sistema sanitario Mercy, insieme con la dirigenza dell'azienda. Metteranno in evidenza l'Eversense 365 nella pratica clinica e forniranno una panoramica della collaborazione commerciale di Senseonics con Mercy. Seguirà una sessione di domande e risposte dal vivo dopo le presentazioni.
Senseonics Holdings (NYSE American: SENS) anunció un evento virtual KOL el 25 de octubre de 2024, a las 11:00 a.m. ET, para discutir el sistema de monitoreo continuo de glucosa Eversense® 365 (CGM). Este sistema de nueva generación, recientemente autorizado por la FDA para personas con diabetes tipo 1 y tipo 2 de 18 años o más, es el primer sistema CGM del mundo con una duración de un año.
El evento contará con la participación del Dr. David T. Ahn del Hoag Medical Group y del Dr. Jeff Ciaramita del sistema de salud Mercy, junto con la gerencia de la empresa. Destacarán el Eversense 365 en la práctica clínica y proporcionarán una visión general de la colaboración comercial de Senseonics con Mercy. Después de las presentaciones habrá una sesión de preguntas y respuestas en vivo.
센소닉스 홀딩스 (NYSE American: SENS)는 2024년 10월 25일 오전 11시(ET)에 Eversense® 365 연속 혈당 모니터링(CGM) 시스템에 대해 논의하는 가상 KOL 이벤트를 발표했습니다. 이 차세대 시스템은 최근 FDA의 승인을 받은 18세 이상의 1형 및 2형 당뇨병 환자를 위한 세계 최초의 1년 CGM 시스템입니다.
이벤트에는 호그 의사 그룹의 Dr. David T. Ahn과 메르시 헬스 시스템의 Dr. Jeff Ciaramita가 회사 경영진과 함께 참석할 예정입니다. 그들은 임상 실무에서 Eversense 365의 중요성을 강조하고 센소닉스의 메르시와의 상업적 협력 개요를 제공할 것입니다. 발표 후에는 라이브 질의응답 세션이 진행됩니다.
Senseonics Holdings (NYSE American: SENS) a annoncé un événement virtuel KOL le 25 octobre 2024 à 11h00 ET pour discuter du système de surveillance continue de la glucose Eversense® 365 (CGM). Ce système de nouvelle génération, récemment approuvé par la FDA pour les personnes atteintes de diabète de type 1 et de type 2 âgées de 18 ans et plus, est le premier système CGM au monde d'une durée d'un an.
L'événement mettra en vedette Dr. David T. Ahn du Hoag Medical Group et Dr. Jeff Ciaramita du système de santé Mercy, ainsi que la direction de l'entreprise. Ils mettront en avant Eversense 365 dans la pratique clinique et fourniront un aperçu de la collaboration commerciale de Senseonics avec Mercy. Une session de questions-réponses en direct suivra les présentations.
Senseonics Holdings (NYSE American: SENS) hat am 25. Oktober 2024 um 11:00 Uhr ET ein virtuelles KOL-Event angekündigt, um über das Eversense® 365 kontinuierliches Glukoseüberwachungssystem (CGM) zu diskutieren. Dieses System der nächsten Generation wurde kürzlich von der FDA genehmigt und richtet sich an Personen mit Typ-1- und Typ-2-Diabetes ab 18 Jahren. Es ist das erste CGM-System weltweit mit einer einjährigen Anwendungsdauer.
Das Event wird Dr. David T. Ahn von der Hoag Medical Group und Dr. Jeff Ciaramita vom Mercy Gesundheitssystem sowie das Unternehmensmanagement präsentieren. Sie werden Eversense 365 in der klinischen Praxis hervorheben und einen Überblick über die kommerzielle Zusammenarbeit von Senseonics mit Mercy geben. Im Anschluss an die Präsentationen wird es eine Live-Q&A-Session geben.
- FDA clearance for Eversense 365 CGM system for Type 1 and Type 2 diabetes patients
- World's first one-year CGM system, representing a significant breakthrough in diabetes technology
- Commercial collaboration with Mercy health system
- None.
Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management
GERMANTOWN, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host a virtual KOL event on Friday, October 25, 2024 at 11:00am ET. To register, click here.
The event will feature David T. Ahn, MD, and endocrinologist and Chief of Diabetes Services at Hoag Medical Group, and Jeff Ciaramita, MD, President, Speciality Service Lines at Mercy, who will join company management to discuss the next-generation Eversense® 365 Continuous Glucose Monitoring (CGM) system, which was recently cleared by the U.S. Food and Drug Administration (FDA) for people with Type 1 and Type 2 diabetes aged 18 years and older.
The event will highlight Eversense 365 in clinical practice and include an overview of Senseonics' commercial collaboration with the St. Louis-based healthcare system Mercy. Eversense 365, the world’s first one-year CGM system, represents a significant breakthrough in diabetes technology and management that is highly differentiated from short-term CGMs.
A live question and answer session will follow the formal presentations.
Registration details can be found here. For those who are unable to attend live, a replay will be available by clicking here.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see www.eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Mercy
Mercy, one of the 20 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized care and one of the nation’s largest and highest performing Accountable Care Organizations in quality and cost. Mercy is a highly integrated, multi-state health care system including more than 50 acute care and specialty (heart, children’s, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 900 physician practice locations and outpatient facilities, more than 4,500 physicians and advanced practitioners and 50,000 co-workers serving patients and families across Arkansas, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. In fiscal year 2023 alone, Mercy provided more than half a billion dollars of free care and other community benefits, including traditional charity care and unreimbursed Medicaid.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
Mercy Communications Contact
Bethany Pope 314-251-4472
Mercy Media Relations
Bethany.Pope@Mercy.Net
FAQ
What is the Eversense 365 CGM system and when was it FDA cleared?
When is Senseonics (SENS) hosting the virtual KOL event for Eversense 365?
Who are the key opinion leaders participating in Senseonics' (SENS) Eversense 365 event?
What will be discussed during Senseonics' (SENS) virtual KOL event on Eversense 365?
